Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines

Clinica Terapeutica

Volumn 163, Issue 5, 2012, Pages

  Baldini, E ^a   Sorrenti, S ^a   D'Armiento, E ^a   Guaitoli, E ^a   Morrone, S ^a   D'Andrea, V ^a   Gnessi, L ^a   Moretti, C ^b   Antonelli, A ^c   Catania, A ^a   De Antoni, E ^a   Ulisse, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Anaplastic thyroid cancer; Aneuploidy; Aurora kinases; Cell cycle; Mitosis; SNS 314 mesylate

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; HISTONE H3; SNS 314; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CANCER; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG EFFECT; ENZYME INHIBITION; IMMUNOFLUORESCENCE; IN VITRO STUDY; MITOSIS; POLYPLOIDY; PROTEIN PHOSPHORYLATION; TIME LAPSE IMAGING; WESTERN BLOTTING;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; HUMANS; MESYLATES; PHENYLUREA COMPOUNDS; THIAZOLES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84875637500     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11
2. Trimboli P, Ulisse S, Graziano FM, et al. Trend in thyroid carcinoma size, age at diagnosis and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 2006; 16:1151-5.
3. Trimboli P, Ulisse S, D'Alò M, et al. Analysis of clinical, ultrasound and colour flow-doppler characteristics in predicting malignancy in follicular thyroid neoplasms. Clin Endocrinol 2008; 69:342-6
4. Sorrenti S, Trimboli P, Catania A, et al. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid 2009; 19:355-60
5. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13:453-64
6. Fagin JA. Branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 2002; 16:903-11
7. Troncone G, Volante M, Iaccarino A, et al. Cyclin Di and D3 overexpression predicts malignant behaviour in thyroid fine-needle aspirates suspicious for Hurtle cell neoplasms. Cancer Cytopathol 2009; 117:522-9
8. Pasquali D, Santoro A, Bufo P, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases and BRAF mutation. Thyroid 2011; 21:391-9
9. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. Ca Cancer J Clin 2009; 59:225-49
10. Gospodarowicz MK, Henson DE, Hutter RVP, et al. Progno stic factors in cancer. 2nd ed. International Union Against Cancer. New York, Wiley-Liss, 2001
11. Ulisse S, Baldini E, Sorrenti S, et al. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clinl Endocrinol Metab 2011; 96:504-8
12. Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clinical Endocrinol 2012; doi: 10.1111/j.1365-2265.2012.04465.x.
13. Shahedian B, Shi Y, Zou M, et al. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Gen Metab 2001; 72:155-63
14. Rodrigues RF, Roque L, Rosa-Santos J, et al. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. Br J Cancer 2004; 90:492-6
15. Wreesmann VB, Ghossein RA, Patel SG, et al. Genome-wide appraisal of thyroid cancer progression. Am J Pathol 2002; 161:1549-56
16. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6:1833-9
17. Takahashi T, Futamura M, Yoshimi N, et al. Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000; 91:1007-14
18. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001; 84:824-31
19. Miyoshi Y, Iwao K, Egawa C, et al. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001; 92:370-3
20. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999; 91:1160-2
21. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62:5168-77
22. Ulisse S, Delcros JG, Baldini E, et al. Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 2006; 119:275-82
23. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005; 90:928-35
24. Ulisse S, Baldini E, Toller M, et al. Transforming acidid coliled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr-Relat Cancer 2007; 14:827-37
25. Baldini E, Arlot-Bonnemains Y, Sorrenti S, et al. Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT. BMC Cancer 2011; 11:411
26. Baldini E, Arlot-Bonnemains Y, Mottolese M, et al. Deregulation of Aurora kinases genes expression in human testicular germ cell tumors. Andrologia 2010; 42:260-7
27. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2:21-32
28. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4:842-54
29. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004; 113:211-22
30. Gabillard JC, Ulisse S, Baldini E, et al. Aurora-C interacts with and phosphorylates the transforming acidic coiled-coil 1 protein. Biochem Biophys Res Co 2011; 408:647-53
31. Yan X, Cao L, Li Q, et al. Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cell 2005; 10:617-26
32. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10:262-7
33. Green MR, Woolery JE, Mahadevan D. Update on Aurora Kinase Targeted Therapeutics in Oncology. Expert Opin Drug Discov 2011; 6:291-307
34. Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anti-Cancer Agent Med 2012; 12:87-93
35. Ulisse S, Arlot-Bonnemains Y, Baldini E, et al. Inhibition of the Aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity. J Endocrinol 2010; 204:135-42
36. Mortlock AA, Keen NJ, Jung FH, et al. Progress in the development of selective inhibitors of Aurora kinase. Curr Top Med Chem 2005; 5:807-21
37. Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocrine-Related Cancer 2008; 15:559-68
38. Arbitrario JP, Belmont BJ, Evanchik MJ, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol 2010; 65:707-17
39. Ulisse S, Baldini E, Motolese M, et al. Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomas. BMC Cancer 2010; 10:151
40. Crosio C, Fimia GM, Loury R, et al. Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian aurora kinases. Mol Cell Biol 2002; 22:874-85.